Geode Capital Management
BBIO icon

Geode Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Geode Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$255M Sell
3,418,419
-1,499,611
-30% -$105M 0.01% 698
2026
Q1 		$372M Buy
4,918,030
+505,507
+11% +$36.6M 0.02% 527
2025
Q4 		$345M Buy
4,412,523
+502,582
+13% +$33M 0.02% 535
2025
Q3 		$203M Buy
3,909,941
+228,361
+6% +$11.1M 0.01% 696
2025
Q2 		$159M Buy
3,681,580
+178,686
+5% +$6.5M 0.01% 754
2025
Q1 		$121M Buy
3,502,894
+85,201
+2% +$2.87M 0.01% 860
2024
Q4 		$93.8M Buy
3,417,693
+3,744
+0.1% +$96.8K 0.01% 1039
2024
Q3 		$86.9M Buy
3,413,949
+123,540
+4% +$3.24M 0.01% 1079
2024
Q2 		$83.4M Buy
3,290,409
+427,564
+15% +$11.7M 0.01% 1040
2024
Q1 		$88.5M Buy
2,862,845
+148,677
+5% +$5.06M 0.01% 994
2023
Q4 		$110M Buy
2,714,168
+202,988
+8% +$6.1M 0.01% 813
2023
Q3 		$66.2M Buy
2,511,180
+91,810
+4% +$2.61M 0.01% 1034
2023
Q2 		$41.6M Buy
2,419,370
+166,212
+7% +$2.5M ﹤0.01% 1377
2023
Q1 		$37.4M Buy
2,253,158
+187,251
+9% +$2.18M ﹤0.01% 1388
2022
Q4 		$15.7M Buy
2,065,907
+102,030
+5% +$977K ﹤0.01% 1935
2022
Q3 		$19.5M Sell
1,963,877
-6,569
-0.3% -$68.3K ﹤0.01% 1755
2022
Q2 		$17.9M Buy
1,970,446
+185,870
+10% +$1.55M ﹤0.01% 1840
2022
Q1 		$18.1M Sell
1,784,576
-142,835
-7% -$1.47M ﹤0.01% 1960
2021
Q4 		$32.1M Sell
1,927,411
-19,674
-1% -$832K ﹤0.01% 1642
2021
Q3 		$91.3M Buy
1,947,085
+123,147
+7% +$6.6M 0.01% 854
2021
Q2 		$111M Buy
1,823,938
+160,981
+10% +$9.19M 0.02% 742
2021
Q1 		$102M Buy
1,662,957
+453,236
+37% +$29.7M 0.02% 742
2020
Q4 		$86M Buy
1,209,721
+51,066
+4% +$2.46M 0.01% 774
2020
Q3 		$43.5M Buy
1,158,655
+425,720
+58% +$13.4M 0.01% 993
2020
Q2 		$23.9M Buy
732,935
+10,198
+1% +$311K 0.01% 1377
2020
Q1 		$21M Buy
722,737
+375,359
+108% +$11.6M 0.01% 1261
2019
Q4 		$12.2M Buy
347,378
+11,930
+4% +$331K ﹤0.01% 1874
2019
Q3 		$7.2M Buy
+335,448
New +$9.28M ﹤0.01% 2153

Other funds holding BBIO

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management's BBIO Position: Q2 2026 in Review

Geode Capital Management reduced its BridgeBio Pharma (BBIO) stake by 30% in Q2 2026, selling an estimated $105M and leaving 3,418,419 shares worth $255M. The position accounts for 0.01% of the portfolio, ranked #698.

Geode Capital Management first reported a position in BBIO in Q3 2019 and has held it in 28 quarters since. The position peaked at $372M in Q1 2026. 357 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Geode Capital Management held 3,418,419 shares of BridgeBio Pharma worth $255M as of Q2 2026.
  • Geode Capital Management sold 1,499,611 BridgeBio Pharma shares in Q2 2026, an estimated $105M.
  • BridgeBio Pharma made up 0.01% of Geode Capital Management's portfolio in Q2 2026, its #698 holding.
  • Geode Capital Management first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 28 quarters since.
  • Geode Capital Management's BridgeBio Pharma position peaked at $372M in Q1 2026.
  • 357 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.